AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing
2023年7月25日 - 5:05AM
ビジネスワイヤ(英語)
PTAB rejects request by Berkeley Lights to reconsider its
decision denying Berkeley's argument that AbCellera’s U.S. patent
is invalid
AbCellera (Nasdaq: ABCL) announced that the United States Patent
and Trademark Office’s (USPTO) Patent Trial and Appeal Board (PTAB)
has denied a rehearing request in an Inter Partes Review (IPR)
filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged
AbCellera’s U.S. Patent No. 10,087,408 (the ‘408 Patent).
AbCellera’s ‘408 Patent is directed to microfluidic devices and
using such devices to culture cells, monitor a response, and
recover selected cells, an important part of AbCellera’s end-to-end
monoclonal antibody development engine.
The IPR proceeding stems from AbCellera and the University of
British Columbia (UBC) suing Berkeley Lights for patent
infringement, which is currently pending in the United States
District Court for the Northern District of California. In response
to AbCellera’s infringement claims, Berkeley Lights filed three
separate petitions with the PTAB seeking to invalidate multiple
patents. The PTAB previously rejected two of Berkeley Lights’
petitions, disagreeing that certain challenged claims were invalid.
Berkeley Lights challenged the claims of the ‘408 Patent alleging
invalidity based on anticipation and obviousness over the prior
art. In a written unanimous decision, the PTAB rejected all of
Berkeley Lights’ arguments and confirmed that all claims of
AbCellera’s ‘408 Patent are valid. Thereafter, Berkeley Lights
sought rehearing and the PTAB again rejected Berkeley Lights’
claims.
“The PTAB’s decision denying Berkeley Lights’ rehearing request
fortifies the strength of our microfluidic cell-culture-system
patent claims,” said Tryn Stimart, J.D., Chief Legal and Compliance
Officer of AbCellera. “AbCellera is committed to protecting its
intellectual property portfolio. We look forward to the District
Court resuming our patent infringement cases against Berkeley
Lights.”
About AbCellera Biologics Inc.
AbCellera is breaking the barriers of conventional antibody drug
discovery to bring better medicines to patients, sooner.
AbCellera’s engine integrates expert teams, technology, and
facilities with the data science and automation needed to propel
antibody-based medicines from target to clinic in nearly every
therapeutic area with precision and speed. AbCellera provides
innovative biotechs and leading pharmaceutical companies with a
competitive advantage that empowers them to move quickly, reduce
cost, and tackle the toughest problems in drug development. For
more information, please visit www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230724204358/en/
AbCellera:
Media: Jessica Yingling, Ph.D.; media@abcellera.com,
+1(236)521-6774 Business Development: Murray McCutcheon, Ph.D.;
bd@abcellera.com, +1(604)559-9005 Investor Relations: Josephine
Hellschlienger, Ph.D.; ir@abcellera.com, +1(778)729-9116
AbCellera Biologics (NASDAQ:ABCL)
過去 株価チャート
から 4 2024 まで 5 2024
AbCellera Biologics (NASDAQ:ABCL)
過去 株価チャート
から 5 2023 まで 5 2024